Treatment of Older Patients with Acute Lymphoblastic Leukaemia

Area of Science:

• Hematology
• Oncology
• Geriatric Medicine

Background:

• Adult acute lymphoblastic leukemia (ALL) outcomes have improved due to intensive chemotherapy, yet older patients experience less benefit.
• Older ALL patients present with lower complete remission rates, higher early mortality, increased relapse rates, and inferior survival compared to younger patients.
• Intensive chemotherapy regimens, even with stem-cell transplantation, are less tolerated in the elderly ALL population, compounded by age-related prognostic factors.

Purpose of the Study:

• To review the current challenges and advancements in treating adult acute lymphoblastic leukemia (ALL) in older patients.
• To highlight the need for age-adapted treatment strategies and novel therapeutic approaches for elderly ALL patients.
• To emphasize the necessity of prospective clinical trials tailored for older individuals with ALL.

Main Methods:

• Review of current literature on adult acute lymphoblastic leukemia (ALL) treatment outcomes, focusing on age-related differences.
• Analysis of treatment tolerance and prognostic factors in elderly versus younger ALL patients.
• Evaluation of emerging therapeutic strategies, including targeted therapies and modified transplantation protocols.

Main Results:

• Significant improvements in adult ALL outcomes are primarily driven by pediatric-inspired chemotherapy, with less pronounced gains in older populations.
• Older patients exhibit poorer response rates, higher treatment-related mortality, and reduced survival, alongside increased susceptibility to intensive therapies.
• Age-adapted chemotherapy for Ph/BCR-ABL-negative ALL and tyrosine kinase inhibitors for Ph/BCR-ABL-positive ALL show promise.

Conclusions:

• Further progress in adult ALL treatment for older patients requires novel targeted therapies, particularly immunotherapies, and optimized consolidation strategies.
• Reduced-intensity stem-cell transplantation may offer a viable option for select elderly ALL patients.
• Urgent initiation of prospective clinical trials specifically designed for older adult ALL patients is essential to advance care and improve survival outcomes.